
BioNTech
BioNTech was founded by scientists and physicians to translate science into survival by combining fundamental research and operational excellence. We at BioNTech believe that the …
BioNTech - Wikipedia
BioNTech SE (/ biːˈɒntɛk / bee-ON-tek; or / baɪˈɒntɛk / bye-ON-tek[3] short for Biopharmaceutical New Technologies) is a global biotechnology company headquartered in Mainz that develops …
BioNTech US
BioNTech US is a fully integrated subsidiary with a strong foundation in Europe and a focus on the development of novel neoantigen-targeted T cell therapies, complementing BioNTech’s highly …
FDA puts clinical hold on BioNTech’s malaria vaccine trial
3 hours ago · BioNTech made its name in the mRNA field after it co-developed a Covid-19 vaccine with Pfizer. mRNA vaccines were heavily utilised during the Covid-19 pandemic, with …
BioNTech | Our mission: basic research in mRNA technology and …
BioNTech is a fully integrated, global immunotherapy powerhouse. We have been working on automated and digitized processes and build continuously capabilities for specialized …
Welcome to our investor page | BioNTech
Nov 4, 2024 · Biopharmaceutical New Technologies, or BioNTech, is a global, fully integrated next-generation immunotherapy company pioneering novel therapies for cancer, infectious …
BioNTech Completes Acquisition of Biotheus | BioNTech
Feb 3, 2025 · About BioNTech Biopharmaceutical New Technologies (BioNTech) is a global next generation immunotherapy company pioneering novel investigative therapies for cancer and …
Pfizer and BioNTech Provide Update on mRNA-based …
Aug 16, 2024 · NEW YORK & MAINZ, Germany--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced top-line results …
U.S. FDA places clinical hold on BioNTech's malaria vaccine study
21 hours ago · March 4 (Reuters) - BioNTech (22UAy.DE), opens new tab said in a regulatory filing on Tuesday the U.S. Food and Drug Administration has placed a clinical hold on an early …
BioNTech and DualityBio Form Global Strategic Partnership to …
Apr 3, 2023 · BioNTech receives exclusive licenses from DualityBio for two investigational antibody-drug conjugate assets (DB-1303 and DB-1311) directed against targets expressed in …